Jawahar L. Mehta
Distingusihed Professor
Also affiliated: Northwestern University (2006); Western University (1997); Merck & Co., Inc., Rahway, NJ, USA (United States) (2018); United States Department of Veterans Affairs (1990–1995); UF Health Shands Hospital (2015); University of Arizona (2021); University of Georgia (1987); American Association of Colleges of Pharmacy (1987–1990); University of Arkansas Medical Center (2014–2024); Veterans Health Administration (1998); University of Florida Health (1994); University of Florida (1981–2003); Arkansas Cardiology (2023); Central Arkansas Veterans Healthcare System (2003–2025); Maine Farmland Trust (1998); North Florida/South Georgia Veterans Health System (1991); Banner - University Medical Center Tucson (2021); Department of Veterans Affairs (1998); Nuclear Research Institute Rez (Czechia) (1996); Florida College (1987–2000)
Faculty Researcher
Internal Med, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Jawahar L. Mehta, Distinguished Professor in Internal Medicine at the University of Arkansas for Medical Sciences, has published extensively on cardiovascular diseases, particularly in the context of COVID-19 and its related complications. His research group has investigated mechanisms such as NF-κB as a potential therapeutic target in cardiovascular diseases and explored the cardioprotective effects of MSC exosomes in ischemic heart conditions.
Dr. Mehta has also conducted meta-analyses and systematic reviews on critical public health topics. These include the efficacy and safety of sodium-glucose cotransporter 2 inhibitors in heart failure patients, the effect of aspirin on mortality in COVID-19, and the association of lipid levels with COVID-19 infection severity and mortality. His work also examines specific aspects of COVID-19, such as vaccine-related myocarditis and cerebral venous sinus thrombosis, as well as the relationship between HDL cholesterol levels and susceptibility to the virus.
With an h-index of 32 and over 6,500 citations across 119 publications, Dr. Mehta is recognized as a highly cited researcher. He frequently collaborates with colleagues at the University of Arkansas for Medical Sciences, including Nishank Jain, Subhi J. Al’Aref, Srinivas Ayyadevara, and J. Curran Henson.
Metrics
- h-index: 33
- Publications: 119
- Citations: 6,605
Selected Publications
-
Time-Dependent Association Between Breast Cancer and Risk of Ischemic Stroke (2026)
-
D101-04 Lox-1 Promotes Lung Homeostasis and Repair via Neutrophils in a Pathogen-Dependent Manner (2026)
-
Disulfidptosis: A novel cell death mechanism with pathological significance and therapeutic potential in diseases (2026)
-
Knowledge gaps in revascularization strategies in the setting of type II myocardial infarction: A common clinical dilemma in contemporary practices (2026)
-
Functional Biochemistry of Iron and Its Cardiopulmonary Impact (2026)
-
Remodelling-derived pre-β1 and remnant HDL particles: a snapshot of reverse cholesterol transport dynamics and efficiency (2025)
-
LOX-1+ Neutrophils Exhibit a Distinct Phenotype Associated With Prevention of Lung Injury During Pneumonia (2025)
-
Molecular Insights into Ischemia–Reperfusion Injury in Coronary Artery Disease: Mechanisms and Therapeutic Implications: A Comprehensive Review (2025)
-
Addressing myocardial infarction in South-Asian populations: risk factors and machine learning approaches (2025)
-
The pleiotropic effects of PCSK9 in cardiovascular diseases beyond cholesterol metabolism (2025)
-
Reply (2024)
-
Applications of ChatGPT in Heart Failure Prevention, Diagnosis, Management, and Research: A Narrative Review (2024)
-
Positive Implications of Introducing Mindfulness Techniques as a Platform for Preoperative Stress Reduction to Improve Patient Outcomes Postpercutaneous Coronary Intervention (2024)
-
‘Exerkines’: A Comprehensive Term for the Factors Produced in Response to Exercise (2024)
-
COVID-19 in the Initiation and Progression of Atherosclerosis (2024)
Federal Grants 1
PCSK9-A novel target for the treatment of myocardial ischemia
Grants & Funding
As listed on this researcher's institutional profile. Federal awards with verified records are shown above.
- Anti-myeloma efficacy of FAP inhibitor in ex vivo and in vivo systems for primary myeloma Vantia Therapeutics Ltd. Principal Investigator
- Structure based drug design for atherosclerosis targeted at LOX-1, a receptor for oxidized low-density lipoprotein American Heart Association (SouthWest Affiliate) Co-Investigator
- Regulation of LOX-1 Expression by Pioglitazone Takeda Principal Investigator
- TOPCAT: Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone AnTagonist NIH/Nat. Heart, Lung & Blood Institute via New England Research Insts., Inc. Principal Investigator
Collaboration Network
Top Collaborators
- Cerebral Venous Sinus Thrombosis following COVID-19 Vaccination: Analysis of 552 Worldwide Cases
- COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis
- ‘Exerkines’: A Comprehensive Term for the Factors Produced in Response to Exercise
- Insights on Kawasaki disease and multisystem inflammatory syndrome: relationship with COVID-19 infection
- Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines
Showing 5 of 12 shared publications
- Association of Lipid Levels With COVID-19 Infection, Disease Severity and Mortality: A Systematic Review and Meta-Analysis
- HDL cholesterol levels and susceptibility to COVID-19
- COVID-19 in the Initiation and Progression of Atherosclerosis
- Vegetarianism, microbiota, and cardiovascular health: looking back, and forward
- Persistent cardiac injury – An important component of long COVID-19 syndrome
Showing 5 of 12 shared publications
- Association of Lipid Levels With COVID-19 Infection, Disease Severity and Mortality: A Systematic Review and Meta-Analysis
- HDL cholesterol levels and susceptibility to COVID-19
- COVID-19 in the Initiation and Progression of Atherosclerosis
- Vegetarianism, microbiota, and cardiovascular health: looking back, and forward
- Persistent cardiac injury – An important component of long COVID-19 syndrome
Showing 5 of 12 shared publications
- Cerebral Venous Sinus Thrombosis following COVID-19 Vaccination: Analysis of 552 Worldwide Cases
- COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis
- Insights on Kawasaki disease and multisystem inflammatory syndrome: relationship with COVID-19 infection
- Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines
- Syndemic: A Synergistic Anthropological Approach to the COVID-19 Pandemic
Showing 5 of 10 shared publications
- MSC exosome-mediated cardioprotection in ischemic mouse heart comparative proteomics of infarct and peri-infarct areas
- Updates on New Therapies for Patients with CKD
- Proteomic basis of modulation of postischemic fibrosis by MSC exosomes
- Mesenchymal Stem Cell Treatment for Hyperactive Immune Response in Patients with COVID-19
- Platelet Count and Platelet Volume in Patients with CKD
Showing 5 of 9 shared publications
- NF-κB, A Potential Therapeutic Target in Cardiovascular Diseases
- MSC exosome-mediated cardioprotection in ischemic mouse heart comparative proteomics of infarct and peri-infarct areas
- Adverse Cardiovascular Effects of Anti-COVID-19 Drugs
- LOX-1 Deletion Attenuates Myocardial Fibrosis in the Aged Mice, Particularly Those With Hypertension
- NF-Κb, A Potential Therapeutic Target, In Cardiovascular Diseases
Showing 5 of 8 shared publications
- Updates on New Therapies for Patients with CKD
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Potent Antiplatelet Therapy May Reduce Death from Sepsis in Patients on Chronic Dialysis
- Renal Biomarkers in Heart Failure
Showing 5 of 8 shared publications
- Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis
- HDL cholesterol levels and susceptibility to COVID-19
- COVID-19 in the Initiation and Progression of Atherosclerosis
- Applications of ChatGPT in Heart Failure Prevention, Diagnosis, Management, and Research: A Narrative Review
- Renal Biomarkers in Heart Failure
Showing 5 of 7 shared publications
- Association of Lipid Levels With COVID-19 Infection, Disease Severity and Mortality: A Systematic Review and Meta-Analysis
- HDL cholesterol levels and susceptibility to COVID-19
- Does aspirin save lives in patients with COVID-19?
- Impact of Atrial Fibrillation on In-Hospital Outcomes among Hospitalizations for Cardiac Surgery: An Analysis of the National Inpatient Sample
- Higher HDL Cholesterol Levels Decrease Susceptibility to COVID-19 Infection
Showing 5 of 6 shared publications
- COVID-19 Vaccine and Myocarditis
- Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis
- Meta-Analysis of the Effect of Aspirin on Mortality in COVID-19
- Meta-analysis of the Effect of Colchicine on Mortality and Mechanical Ventilation in COVID-19
- Best time for administration of antihypertensive medications: morning or evening?
- Cerebral Venous Sinus Thrombosis following COVID-19 Vaccination: Analysis of 552 Worldwide Cases
- COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis
- Syndemic: A Synergistic Anthropological Approach to the COVID-19 Pandemic
- Cerebral venous thrombosis after COVID-19 vaccines: Do we know the mechanism?
- The long-term cardiovascular impairment of COVID 19: need for clarity in definition and terminology
- Association of Lipid Levels With COVID-19 Infection, Disease Severity and Mortality: A Systematic Review and Meta-Analysis
- HDL cholesterol levels and susceptibility to COVID-19
- Renal Biomarkers in Heart Failure
- Higher HDL Cholesterol Levels Decrease Susceptibility to COVID-19 Infection
- BROMOCRIPTINE USE IN PERIPARTUM CARDIOMYOPATHY:SYSTEMATIC REVIEW AND META ANALYSIS
- MSC exosome-mediated cardioprotection in ischemic mouse heart comparative proteomics of infarct and peri-infarct areas
- Adverse Cardiovascular Effects of Anti-COVID-19 Drugs
- Proteomic basis of modulation of postischemic fibrosis by MSC exosomes
- Author Correction: Molecular events in MSC exosome mediated cytoprotection in cardiomyocytes
- MSC exosome-mediated cardioprotection in ischemic mouse heart comparative proteomics of infarct and peri-infarct areas
- Author Correction: Molecular events in MSC exosome mediated cytoprotection in cardiomyocytes
- Proteomic Analysis of Transcription Factors Involved in the Alteration of Ischemic Mouse Heart as Modulated by MSC Exosomes
- Proteomic analysis of transcription factors involved in the alteration of ischemic mouse heart as modulated by MSC exosomes
- MSC exosome-mediated cardioprotection in ischemic mouse heart comparative proteomics of infarct and peri-infarct areas
- Author Correction: Molecular events in MSC exosome mediated cytoprotection in cardiomyocytes
- Proteomic Analysis of Transcription Factors Involved in the Alteration of Ischemic Mouse Heart as Modulated by MSC Exosomes
- Proteomic analysis of transcription factors involved in the alteration of ischemic mouse heart as modulated by MSC exosomes
Similar Researchers
Based on overlapping research topics